Fast-casual Ohio-based US restaurant brand City BBQ has formed a partnership with customer data platform Bikky to drive ...
2d
GlobalData on MSNMAIA’s lung cancer therapy 99% more likely to improve OS over chemo aloneA treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...
6d
Zacks.com on MSNRegeneron to Report Q4 Earnings: Is a Beat in the Cards?Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...
Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...
Learn more. For more information on how we test products, click here. The best tennis brands combine style and comfort for the utmost performance on the court. Unlike the best golf clothing brands, ...
Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...
Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...
Stray Kids’ leader Bang Chan has officially been named the new brand ambassador for Italian luxury fashion house Fendi! On January 16, Fendi made the exciting announcement through its social ...
Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...
Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results